Literature DB >> 30207979

Can naloxone prescription and overdose training for opioid users work in family practice? Perspectives of family physicians.

Pamela Leece1, Aaron Orkin2, Rita Shahin3, Leah S Steele4.   

Abstract

OBJECTIVE: To explore family physicians' attitudes toward prescribing naloxone to at-risk opioid users, as well as to determine the opportunities and challenges for expanding naloxone access to patients in family practice settings.
DESIGN: One-hour focus group session and SWOT (strengths, weaknesses, opportunities, and threats) analysis.
SETTING: Workshop held at the 2012 Family Medicine Forum in Toronto, Ont. PARTICIPANTS: Seventeen conference attendees from 3 Canadian cities who practised in various family practice settings and who agreed to participate in the workshop.
METHODS: The workshop included an overview of information about naloxone distribution and overdose education programs, followed by group discussion in smaller focus groups. Participants were instructed to focus their discussion on the question, "Could this [overdose education and naloxone prescription] work in your practice?" and to record notes using a standardized discussion guide based on a SWOT analysis. Two investigators reviewed the forms, extracting themes using an open coding process. MAIN
FINDINGS: Some participants believed that naloxone could be used safely among family practice patients, that the intervention fit well with their clinical practice settings, and that its use in family practice could enhance engagement with at-risk individuals and create an opportunity to educate patients, providers, and the public about overdose. Participants also indicated that the current guidelines and support systems for prescribing or administering naloxone were inadequate, that medicolegal uncertainties existed for those who prescribed or administered naloxone, and that high-quality evidence about the intervention's effectiveness in family practice was lacking.
CONCLUSION: Family physicians believe that overdose education and naloxone prescription might provide patients at risk of opioid overdose in their practices with broad access to a potentially lifesaving intervention. However, they explain that there are key barriers currently limiting widespread implementation of naloxone use in family practice settings. Copyright© the College of Family Physicians of Canada.

Entities:  

Year:  2015        PMID: 30207979      PMCID: PMC4463897     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  16 in total

Review 1.  Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.

Authors:  Louisa Degenhardt; Chiara Bucello; Bradley Mathers; Christina Briegleb; Hammad Ali; Matt Hickman; Jennifer McLaren
Journal:  Addiction       Date:  2010-11-04       Impact factor: 6.526

2.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

Review 3.  Reducing the health consequences of opioid addiction in primary care.

Authors:  Sarah Bowman; Julie Eiserman; Leo Beletsky; Sharon Stancliff; R Douglas Bruce
Journal:  Am J Med       Date:  2013-05-08       Impact factor: 4.965

4.  Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders.

Authors:  Traci C Green; Sarah E Bowman; Nickolas D Zaller; Madeline Ray; Patricia Case; Robert Heimer
Journal:  Subst Use Misuse       Date:  2013-05       Impact factor: 2.164

5.  Opioid dose and drug-related mortality in patients with nonmalignant pain.

Authors:  Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; J Michael Paterson; David N Juurlink
Journal:  Arch Intern Med       Date:  2011-04-11

6.  Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities.

Authors:  Leo Beletsky; Robin Ruthazer; Grace E Macalino; Josiah D Rich; Litjen Tan; Scott Burris
Journal:  J Urban Health       Date:  2007-01       Impact factor: 3.671

7.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

8.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-17       Impact factor: 17.586

9.  Trends in opioid use and dosing among socio-economically disadvantaged patients.

Authors:  Tara Gomes; David N Juurlink; Irfan A Dhalla; Angela Mailis-Gagnon; J Michael Paterson; Muhammad M Mamdani
Journal:  Open Med       Date:  2011-01-25

10.  Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada.

Authors:  Parvaz Madadi; Doris Hildebrandt; Albert E Lauwers; Gideon Koren
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more
  3 in total

1.  Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision.

Authors:  Tomás Barry; Jan Klimas; Helen Tobin; Mairead Egan; Gerard Bury
Journal:  Br J Gen Pract       Date:  2017-02-28       Impact factor: 5.386

2.  Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.

Authors:  Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Caitlin Turner; Nina C Santos; Phillip O Coffin
Journal:  J Gen Intern Med       Date:  2016-11-04       Impact factor: 5.128

3.  Protocol for a mixed-methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) randomised control trial.

Authors:  Aaron Orkin; Douglas Campbell; Curtis Handford; Shaun Hopkins; Michelle Klaiman; Pamela Leece; Janet A Parsons; Rita Shahin; Carol Strike; Kevin Thorpe; Kate Sellen; Geoffrey Milos; Amy Wright; Mercy Charles; Ruby Sniderman; Laurie Morrison
Journal:  BMJ Open       Date:  2019-11-12       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.